TRICALS is the largest European research initiative to find a cure for ALS to date. Forty-eight top research centres in sixteen countries have joined hands with patient organisations and fundraisers to reach our one goal: find effective treatments for ALS.

TRICALS is an independent consortium of leading ALS experts, patients, and patient advocacy groups across Europe. The mission of TRICALS is to find effective treatments for ALS by collaborating on a large, international scale.

The goal of Precision ALS is aligned with the goal of TRICALS, similar to Precision ALS is: to provide the right patient with the right treatment at the right time. This will require a precision-based medicine approach to overcome the challenges of disease heterogeneity and clinical variance between patients. Precision medicine requires the analysis of large amounts of data to make new discoveries. Therefore, as ALS is a rare disease, no single site can individually achieve this goal – collaboration is necessary.

Members of the TRICALS Consortium have established population-based Registers with linked genomic and patient journey data. TRICALS members have published individually and collectively on a range of areas of interest, including genomics, patient journey pathways and predictors of survival. TRICALS partners have also participated in both industry-sponsored, and investigator-led clinical trials and observational studies.

As part of Precision ALS, data from the population-based Registers of each of the participating TRICALS sites will be used by Precision ALS to conduct a detailed analysis of the effect of genomic variants among ALS patients. Participating sites will also participate in Precision ALS prospectively by collecting data from ALS patients at multiple timepoints, to accurately record each patient’s journey. This data will then be uploaded onto our purpose-built Patient Data Platform, where it will provide a rich dataset for researchers to access and analyse.

TRICALS will support this programme wholly and fully over the four years of the research programme and beyond.